NCT06295679

A Study Assessing Repatha® in Combination With Standard of Care (SOC) Compared With SOC on Major Cardiovascular Events in Chinese Participants With Atherosclerotic Cardiovascular Disease

A Real-world, Prospective, Observational Study Assessing the Effectiveness of Repatha® Used in Combination With Standard of Care Compared With Standard of Care Alone on Major Cardiovascular Events in Chinese Patients With Established Atherosclerotic Cardiovascular Disease

• Status: Recruiting
• Phase: —
• Study type: Observational
• Enrollment: 7,000 (estimated)
• Sponsor: Amgen · Industry
• Sex: All
• Age: 18 Years – 150 Years
• Healthy volunteers: Not accepted

Summary

The primary objective of the study is to evaluate real-world effectiveness of treatment with Repatha® in combination with SOC, compared with SOC alone, on the risk for cardiovascular (CV) death, myocardial infarction (MI), stroke, hospitalization for unstable angina, or coronary revascularization, whichever occurs first, in participants with established atherosclerotic CV disease (ASCVD) treated with SOC, according to local clinical practice.

Conditions

• Major Cardiovascular Event
• Established Atherosclerotic Cardiovascular Disease

Timeline

• Start date: 2022-12-19
• Primary completion: 2028-12-19
• Completion: 2028-12-19
• First posted: 2024-03-06
• Last updated: 2026-02-20

Locations

90 sites across 1 country: China